#Sweden #Stockholm #Sobi #gout #Arthrosi

Sobi Acquires Arthrosi Therapeutics: A New Hope for Gout Treatment

On February 9, 2026, Swedish Orphan Biovitrum AB, known as Sobi, announced the successful acquisition of Arthrosi Therapeutics, Inc., a strategic move aimed at bolstering Sobi's capabilities in the management of gout. This acquisition is significant not only for Sobi but also for the millions of individuals living with gout, one of the most common forms of inflammatory arthritis.

Strengthening the Pipeline

The inclusion of Arthrosi Therapeutics’ flagship treatment, pozdeutinurad (AR882), into Sobi's existing pipeline presents a groundbreaking advancement in gout management. Pozdeutinurad is classified as a URAT1 inhibitor designed to lower serum uric acid levels in patients with progressive and tophaceous gout. The acquisition signifies Sobi’s commitment to enhancing the quality of care available to those affected.

Arthrosi's pozdeutinurad is currently involved in two Phase 3 global clinical trials, with preliminary data expected in 2026. The results from these studies will be pivotal in assessing the efficacy of pozdeutinurad in providing better outcomes for patients who are inadequately treated by existing therapies.

The Importance of Innovative Therapies

Gout is triggered by elevated levels of uric acid in the body, which can lead to painful flares, joint damage, and chronic complications if left untreated. Many patients experience suboptimal results with existing first-line treatments. The need for innovative therapies like pozdeutinurad becomes crucial as uncontrolled gout is linked to higher incidences of kidney disease and cardiovascular issues.

Clinical trials of pozdeutinurad have shown promising results, including a significant reduction in serum uric acid levels and the resolution of tophi, all while maintaining a favorable safety profile. This progress not only enhances patient care but also represents a potential best-in-class treatment for gout patients.

About Sobi and Arthrosi

Sobi, a global biopharmaceutical company, employs around 1,900 individuals across various regions, including Europe, North America, and Asia, with a focus on rare diseases. Sobi's revenue for 2025 was reported at SEK 28 billion, underscoring its robust market presence.

Arthrosi Therapeutics, based in San Diego, California, is dedicated to developing treatments for serious conditions like gout, an area that has historically seen limited advancements in recent years. The acquisition of Arthrosi aligns seamlessly with Sobi's mission to transform and enhance the quality of life for patients through innovative solutions.

Conclusion

The completion of this acquisition marks a transformative step forward in gout treatment. With pozdeutinurad potentially set to fill a significant gap in existing therapies, Sobi reaffirms its commitment to advancing the landscape of treatment options for gout sufferers. As the clinical trials progress, the anticipation for pozdeutinurad's release grows, offering hope to countless patients seeking effective management of their condition.

This acquisition is not just a corporate transaction; it is a promise of better health outcomes for patients enduring the painful realities of gout. As Sobi moves forward in its mission, collaborative efforts will undoubtedly shape the future of gout treatment, paving the way for a brighter tomorrow.